Table 6.
Comparison of good outcome at 1 year
| All Patients n (%) | Groups | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| A (n = 84) | B (n = 114) | |||||||||
| Bad (GOS≦3) | Good (GOS > 3) | P | Bad (GOS≦3) | Good (GOS > 3) | Total | Bad (GOS≦3) | Good (GOS > 3) | Total | P | |
| 145 (73.2) | 53 (26.8) | 51 (60.7) | 33 (39.3) | 84 | 94 (82.5) | 20 (17.5) | 114 | 0.001 | ||
| Age | 0.001 | |||||||||
| ≦60 | 85 (65.4) | 45 (34.6) | 0.001 | 18 (40.0) | 27 (60.0) | 45 | 67 (78.8) | 18 (21.2) | 85 | <0.001 |
| > 60 | 60 (88.2) | 8 (11.8) | 33 (84.6) | 6 (15.4) | 39 | 27 (93.1) | 2 (6.9) | 29 | 0.451 | |
| Gender | 0.001 | |||||||||
| Female | 40 (74.1) | 14 (25.9) | 0.870 | 15 (68.2) | 7 (31.8) | 22 | 25 (78.1) | 7 (21.9) | 32 | 0.417 |
| Male | 105 (72.9) | 39 (27.1) | 36 (58.1) | 26 (41.9) | 62 | 69 (84.1) | 13 (15.9) | 82 | 0.001 | |
| Diabetes | 0.001 | |||||||||
| No | 85 (66.9) | 42 (33.1) | 0.008 | 32 (53.3) | 28 (46.7) | 60 | 53 (79.1) | 14 (20.9) | 67 | 0.002 |
| Yes | 60 (84.5) | 11 (15.5) | 19 (79.2) | 5 (20.8) | 24 | 41 (87.2) | 6 (12.8) | 47 | 0.490 | |
| GCS | <0.001 | 0.004 | ||||||||
| 15-13 (grade 1) | 14 (46.7) | 17 (53.3) | 5 (29.4) | 12 (70.6) | 17 | 9 (69.2) | 4 (30.8) | 13 | 0.033 | |
| 12-7 (grade 2) | 55 (62.5) | 33 (37.5) | 0.130a | 18 (48.6) | 19 (51.4) | 37 | 37 (72.5) | 14 (27.5) | 51 | 0.023 |
| 6-3 (grade 3) | 76 (95.0) | 4 (5.0) | <0.001b | 28 (93.3) | 2 (6.7) | 30 | 48 (96.0) | 2 (4.0) | 50 | 0.705 |
| NIHSS | <0.001 | 0.001 | ||||||||
| <15 (grade 1) | 15 (46.9) | 17 (53.1) | 4 (23.5) | 13 (76.5) | 17 | 11 (73.3) | 4 (26.7) | 15 | 0.006 | |
| 15-20 (grade 2) | 28 (56.0) | 22 (44.0) | 0.422a | 10 (45.5) | 12 (54.5) | 22 | 18 (64.3) | 10 (35.7) | 28 | 0.187 |
| >20 (grade 3) | 102 (87.9) | 14 (12.1) | <0.001b | 37 (82.2) | 8 (17.8) | 45 | 65 (91.5) | 6 (8.5) | 71 | 0.135 |
| HV , mL | 0.001 | |||||||||
| ≦60 | 80 (61.1) | 51 (38.9) | <0.001 | 29 (47.5) | 32 (52.5) | 61 | 51 (72.9) | 19 (27.1) | 70 | 0.003 |
| > 60 | 65 (97.0) | 2 (3.0) | 22 (95.7) | 1 (4.3) | 23 | 43 (97.7) | 1 (2.3) | 44 | 1.000 | |
| IVH | <0.001 | 0.001 | ||||||||
| 0 | 31 (48.4) | 32 (51.6) | 10 (33.3) | 20 (66.7) | 30 | 21 (61.8) | 13 (38.2) | 34 | 0.024 | |
| 1-4 (grade 1) | 43 (69.4) | 19 (30.6) | 0.018c | 14 (51.9) | 13 (48.1) | 27 | 29 (82.9) | 6(17.1) | 35 | 0.009 |
| 5-8 (grade 2) | 36 (100.0) | 0 | <0.001a | 15 (100.0) | 0 | 15 | 21 (100.0) | 0 | 21 | 1.000 |
| 9-12 (grade 3) | 35 (97.2) | 1 (2.8) | 1.000 | 12 (100.0) | 0 | 12 | 23 (95.8) | 1 (4.2) | 24 | 1.000 |
| Complications, n (%) | ||||||||||
| RB | 0.001 | |||||||||
| No | 136 (72.0) | 53 (28.0) | 0.116 | 50 (60.2) | 33 (39.8) | 83 | 86 (81.1) | 20 (18.9) | 106 | 0.002 |
| Yes | 9 (100.0) | 0 | 1 (100.0) | 0 | 1 | 8 (100) | 0 | 8 | 1.000 | |
| RF | 0.001 | |||||||||
| NO | 124 (70.1) | 53 (29.9) | 0.003 | 46 (58.2) | 33 (41.8) | 79 | 78 (79.6) | 20 (20.4) | 98 | 0.002 |
| Yes | 21 (100.0) | 0 | 5 (100.0) | 0 | 5 | 16 (100.0) | 0 | 16 | 1.000 | |
| PI | 0.001 | |||||||||
| No | 70 (60.3) | 46 (39.7) | <0.001 | 22 (44.0) | 28 (56.0) | 50 | 48 (72.7) | 18 (27.3) | 66 | 0.002 |
| Yes | 75 (91.5) | 7 (8.5) | 29 (85.3) | 5 (14.7) | 34 | 46 (95.8) | 2 (4.2) | 48 | 0.120 | |
| UGB | 0.001 | |||||||||
| No | 131 (71.6) | 52 (28.4) | 0.075 | 44 (57.1) | 33 (42.9) | 77 | 87 (82.1) | 19 (17.9) | 106 | <0.001 |
| Yes | 14 (93.3) | 1 (6.7) | 7 (100.0) | 0 | 7 | 7 (87.5) | 1 (12.5) | 8 | 1.000 | |
P values were calculated using the Wilcoxon or Kruskal-Wallis rank sum tests. Groups: A, minimal invasive puncture and drainage; B, decompressive craniectomy; GOS: Glasgow Outcome Scale; BP: blood pressure; SPB systolic blood pressure. DBP: diastolic blood pressure. GCS: Glasgow Coma Scale; NIHSS: National Institutes of Health Stroke Scale; HV: hematoma volume; IVH: intraventricular hemorrhage; RB: rebleed; PI: pulmonary infection; RF: renal failure; UGB: upper gastrointestinal bleeding; agrade 1 vs. grade 2; bgrade 2 vs. grade 3; cIVH 0 vs. IVH grade 1.